Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Post by Sarb99on Dec 31, 2020 11:54am
364 Views
Post# 32203701

When you calculate revenue & profit .40 is nothing

When you calculate revenue & profit .40 is nothing
Just go with 32 testing sites up and running with the last tests per day performed guidance from the company. 32x94 =3008 testing per day can generate 3008x$95=$285,760 and then convert USD to CAD $285,760 x1.29=$368,630. Now 368,630x30=$11,058,912 per month and $132,706,944 per year. 
 
Now calculate the company projected EBITDA of 55%, and you get $72.9 Million, which is more than the current market cap itself. Once you start using the stock market standard, PE Ratio. You will quickly realize .40 cents per share price is nothing. Start using a PE Ratio of 5-10-15 and see where QSC should be in reality. 
 
Now talk about another 13 testing sites coming online in a few days. The next phase is bringing another 63 testing sites by the end of January. These are 76 additional testing sites. Now calculate the revenue from these 76 testing sites, and you will see .40 cents is nothing. 
 
Now imagine the end of March or April with 500 to 700 testing sites. It seems smart money scooping up these shares from penny pinchers. 

<< Previous
Bullboard Posts
Next >>